Video Insights
Video Insights
Advertisement
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
View More
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram explains the use of HIFU and cryotherapy as primary focal therapy modalities, emphasizing a few treatment options.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram explains how advances in focal therapy technologies over the past decade have driven increased use and acceptance.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Carissa Chu, MDProstate Cancer Diagnostics | April 9, 2025
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | April 16, 2025
CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | April 16, 2025
Drs. Joyce and Chang discuss diagnostic strategies and future innovations in managing small renal masses.
Vadim Koshkin, MDUrothelial Carcinoma Diagnostics | April 7, 2025
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Vadim Koshkin, MDUrothelial Carcinoma Diagnostics | April 7, 2025
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | April 7, 2025
Dr. Grivas provides perspective of the long-term outcomes from the JAVELIN Bladder 100 trial as pertaining to older patients.
Scott Tagawa, MD, MS, FACPProstate Cancer | April 4, 2025
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Amar Kishan, MDRLT | April 3, 2025
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
Emmanuel Antonarakis, MDmCSPC | March 31, 2025
Dr. Antonarakis discusses the differences between PARP1 mRNA expression and other biomarkers used for risk stratification.
Michael Morris, MDmHSPC | March 31, 2025
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Thomas Hope, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICDRLT | March 31, 2025
Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.
Advertisement
Advertisement